Keyword: Eylea

News

Bayer Has “Great Plans” for Life Sciences, CEO Says

12.03.2015 - Bayer aims to achieve strong sales and earnings growth for its life science businesses in the coming years, CEO Marijn Dekkers said at the "Meet Management" investor conference in...

News

German Watchdog Says Eylea No Better Than Lucentis

17.12.2014 - Bayer's Eylea (VEGF Trap-Eye) is not more effective than its competitor Lucentis to treat patients with diabetic macular edema, the German Institute for Quality and Efficiency in...

News

Lucentis and Avastin Said to Have Similar Side Effects

16.09.2014 - Roche's cancer drug Avastin as a cheaper treatment for wet age-related macular degeneration (wAMD), a leading cause of blindness in the elderly, does not appear to increase deaths...

News

New Valeant Bid Values Allergan at $49.44 Billion

29.05.2014 - As expected, Canadian drugmaker Valeant Pharmaceuticals International raised the cash component of its offer for Botox manufacturer Allergan on May 28. Its new offer values the US...

News

Bayer’s Eylea AMD Drug Hits Cost Evaluation Hurdle

06.01.2014 - Bayer HealthCare has hit a stumbling block in the sales campaign for its new drug Eylea (aflibercept), or VEGF Trap-Eye, recommended for treatment of age-related wet macula...

News

Bayer Divestment of its MaterialScience Unit ‘Inevitable,’ Analysts Say

30.07.2013 - Expectations that Bayer will embrace a trend in the pharma sector to split off non-core units may be too far ahead of the curve. The diversified German healthcare group has an...

News

Fast Climbing Biotech Regeneron Still Has Room to Grow

07.05.2013 - Just two years ago, Regeneron Pharmaceuticals was a relatively obscure biotech company in the village of Tarrytown, a picturesque New York suburb better known for "Rip Van Winkle,"...

News

Regeneron Says Sanofi to Boost Stake in its Shares

11.02.2013 - Regeneron Pharmaceuticals said its longtime drug-development partner Sanofi aims to boost its stake in the U.S. biotechnology company through open market purchases of its stock...